Observational Study of Kibow Biotics in Chronic Kidney Failure Patients
Recruitment status was Recruiting
A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM". However, it is also referred to as enteric toxin reduction technology. Our hypothesis is to assess the potential benefits in devising a bowel-based probiotic formulation (Kibow® Biotics/RenadylTM) as a dietary supplement product for patients undergoing standardized care of treatment for their CKD stage 3 and stage 4 conditions.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Chronic Kidney Failure Patients, in Conjunction With Standardized Care of Treatment|
- 15-20% Changes in BUN. [ Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 6 months. ] [ Designated as safety issue: No ]
- 15-20% Change in Creatinine [ Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 6 months ] [ Designated as safety issue: No ]
- Quality of life outcome based on questionnaire. [ Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 6 months ] [ Designated as safety issue: No ]
- To observe inflammatory and oxidative stress biomarkers. [ Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 6 months ] [ Designated as safety issue: No ]Observe inflammatory and stress markers in metabolites from blood serum.
- Observation and analysis of patient fecal matter. [ Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 6 months ] [ Designated as safety issue: No ]Observation and analysis of patient fecal matter to determine bacterial flora levels that are present in the stool.
Biospecimen Retention: Samples With DNA
Blood plasma and serum
|Study Start Date:||July 2011|
|Estimated Study Completion Date:||October 2012|
|Estimated Primary Completion Date:||September 2012 (Final data collection date for primary outcome measure)|
|Chronic Kidney Failure 3/4||
Dietary Supplement: Kibow Biotics/Renadyl
Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 & 4, three capsules three times daily (270 CFU's). Months 5 & 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 & 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
Other Name: Kibow Biotics
Probiotics are increasingly utilized clinically. As their safety and health benefits are established, it is reasonable to anticipate that probiotic bacteria will be incorporated into a growing number of clinical regimens, as a dietary supplement.
Extensive in vitro R&D investigations in Kibow's laboratories
Bacterial strains studied were a mixture of patented and proprietary strains of Streptococcus thermophilus (KB27), Lactobacillus acidophilus (KB31) and Bifidobacterium longum (KB35).
Oral administration of these bacterial formulations, tested in the 5/6th nephrectomized rat model (at Thomas Jefferson University, Phila., PA) and minipig model (at Indiana University, Indianapolis, IN), decreased both blood urea nitrogen (BUN) and serum creatinine (Scr) levels.
Two independent veterinarians investigated the effect of Kibow Biotics® in cats and dogs (of both genders and varying body weights) with moderate to severe kidney failure. Based on positive results, this formulation, marketed and distributed as AzodylTM, is currently licensed for veterinary applications to Vetoquinol USA.
Pilot scale studies, double blind, placebo controlled, cross-over studies for six months conducted in 45 patients in USA, Canada, Argentina, and Nigeria demonstrates reduction of BUN (P>95%) and improved quality of life (P>95%). Decrease in creatinine and uric acid levels were also observed. However, these studies were based on correlating the age of geriatric cats and dogs with moderate to significant kidney failure to human geriatric conditions. The proposed current study is being reevaluated based on correlating the weight basis of animal to human conditions. Hence, this is a does escalation study on ingestion of 1x (90 billion CFU/day), 2x (180 billion CFU/day), and 3x (270 billion CFU/day) dosages.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01450657
|Contact: Stephanie DeLoach, M.D.||firstname.lastname@example.org|
|Contact: Bonita Falkner, M.D.||email@example.com|
|United States, Pennsylvania|
|Thomas Jefferson University||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107|
|Contact: Stephanie DeLoach, M.D. 215-955-1301 firstname.lastname@example.org|
|Principal Investigator: Stephanie DeLoach, M.D.|
|Sub-Investigator: Bonita Falkner, M.D.|
|Principal Investigator:||Stephanie DeLoach, M.D.||Thomas Jefferson University, Philadelphia, PA|